Kesen Xu

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index834citations61works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(14), Cell Adhesion Molecules Research(11), Organ Transplantation Techniques and Outcomes(8), Cholangiocarcinoma and Gallbladder Cancer Studies(7), Cytokine Signaling Pathways and Interactions(7)

Publications61 total

rhIL-1RA increase Gemcitabine chemosensitivity by inhibiting NF-κB Activation from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S4 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S2 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S4 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Data from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S3 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S1 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S2 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Data from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S5 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S5 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S1 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
Figure S3 from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
rhIL-1RA increase Gemcitabine chemosensitivity by inhibiting NF-κB Activation from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
2023Open Access
The current surgical treatment of pancreatic neuroendocrine neoplasms in China: a national wide cross-sectional study
Journal of Pancreatology·2019· 18 citedOpen Access
The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study
Journal of Pancreatology·2019· 27 citedOpen Access
Hypoxia preconditioning protects Ca<sup>2+</sup>-ATPase activation of intestinal mucosal cells against R/I injury in a rat liver transplantation model
World Journal of Gastroenterology·2018· 5 citedOpen Access
Pancreaticoduodenectomy for duodenal papilla carcinoma: A single-centre 9-year retrospective study of 112 patients with long-term follow-up
World Journal of Gastroenterology·2017· 16 citedOpen Access
Dynamic regulation of uncoupling protein 2 expression by microRNA-214 in hepatocellular carcinoma
Bioscience Reports·2016· 24 citedOpen Access
Abate Cytochrome C induced apoptosome to protect donor liver against ischemia reperfusion injury on rat liver transplantation model.
PubMed·2016· 15 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Zhuonan Zhuang(14), Jun Niu(11), Sen Guo(9), Jiayong Wang(9), Huai‐Qiang Ju(8), Mitzi Aguilar(8), Takashi Gocho(8), Tomonori Iida(8), Harold Lee(8), Jianhua Ling(8), Zhongkui Li(8), Jie Fu(8), Davide Melisi(8), Yoichiro Iwakura(8), Jason B. Fleming(8), Paul J. Chiao(8), Zhaoyang Zhang(8), Guangyun Yang(8), Peilong Lian(7), Xiaoqiang Fan(7)